Breaking Finance News

Roth Capital downgraded Galectin Therapeutics (NASDAQ:GALT) from Buy to Sell in a report released earlier today.

Having a price of $2.47, Galectin Therapeutics (NASDAQ:GALT) traded -7.38% lower on the day. With the last close up -29.44% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $1.86 and a 200-day moving average of $1.60. 1,632,130 shares of GALT traded hands, up from an average trading volume of 607,886

Roth Capital has downgraded Galectin Therapeutics (NASDAQ:GALT) from Buy to Sell in a statement released on 09/28/2016.

On 8/15/2016, Zacks Investment Research released a statement on Galectin Therapeutics (NASDAQ:GALT) upped the target price from $0.00 to $2.25 that suggested an upside of 0.16%.

Recent Performance Chart

Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics has 52 week low of $1.08 and a 52 week high of $3.25 and has a market capitalization of $0.

In addition to Roth Capital reporting its stock price target, a total of 3 brokerages have issued a ratings update on the stock. The consensus target price is $8.33 with 1 firm rating the stock a strong buy, 2 firms rating the stock a buy, 0 analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *